AHSG and syringocystadenoma papilliferum: Patients with SCAP had lower levels of Fetuin-A (254.1 ± 94.35 mg/L) than both patients with CAP who did not have SCAP (401.4 ± 130.8 mg/L) and those of the control group (585.1 ± 107.2 mg/L; P < 0.001 for both).